SCHEMBL25844196

SCHEMBL25844196

COc1cc(-c2cn(C)c(=O)c3[nH]ncc23)cc(F)c1C(=O)N1CCC(C(C)C)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACVR1 Q04771 6/20 0.41
BRD4 O60885 7/20 0.39
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
TP53 P04637 1/20 0.36
MAPK1 P28482 1/20 0.36
KMT2A Q03164 1/20 0.36
HSD17B10 Q99714 1/20 0.36
BRD9 Q9H8M2 4/20 0.35
BRD7 Q9NPI1 3/20 0.35
TGFBR1 P36897 5/20 0.34
BMPR1B O00238 1/20 0.34
BMPR1A P36894 1/20 0.34
ACVR1B P36896 1/20 0.34
ACVRL1 P37023 1/20 0.34
TNIK Q9UKE5 1/20 0.34
KCNH2 Q12809 1/20 0.34
TAF1 P21675 1/20 0.34
BRPF1 P55201 1/20 0.34
BPTF Q12830 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25844189 0.90 BRD4 (0.39) ACVR1BRD4KDM4EALDH1A1TP53
SCHEMBL25091094 0.90 BRD4 (0.42) ACVR1BRD4KDM4EALDH1A1TP53
SCHEMBL23798508 0.89 ACVR1 (0.38) ACVR1BRD4KDM4EALDH1A1TP53
SCHEMBL23798050 0.88 ACVR1 (0.51) ACVR1BRD4BRD9TGFBR1BMPR1B
SCHEMBL25852511 0.88 ACVR1 (0.44) ACVR1BRD4KDM4EALDH1A1BRD9
SCHEMBL25844050 0.85 BRD9 (0.51) ACVR1BRD4KDM4EALDH1A1TP53
SCHEMBL23798711 0.85 BRD4 (0.41) ACVR1BRD4ALDH1A1MAPK1BRD9
SCHEMBL25844193 0.85 BRD4 (0.44) BRD4KDM4EALDH1A1TP53MAPK1
SCHEMBL25852376 0.84 BRD4 (0.39) ACVR1BRD4ALDH1A1MAPK1BRD9
SCHEMBL25091944 0.82 ACVR1 (0.43) ACVR1BRD4KDM4EALDH1A1BRD9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11691972-B2 Compounds for targeted degradation of BRD9 C4 THERAPEUTICS, INC. (US) 2023-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11691972-B2 Compounds for targeted degradation of BRD9 BRD9, BRD1, BRWD1 ACVR1 3776/4885BRD4 17/4885KDM4E 2222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.